TY - JOUR
T1 - Real-World Pattern-of-Care Analysis of Primary Cutaneous Lymphomas Radiation Therapy Among European Organisation for Research and Treatment of Cancer Members
AU - Elsayad, Khaled
AU - Guenova, Emmanuella
AU - Fournier, Beatrice
AU - Fernandes, Carolina
AU - Clementel, Enrico
AU - Papadavid, Evangelia
AU - Barry, Marie Beylot
AU - Pavlotsky, Felix
AU - Assaf, Chalid
AU - Ortiz-Romero, Pablo L.
AU - Kouloulias, Vassilis
AU - de Masson, Adele
AU - Dalle, Stephane
AU - Clavère, Pierre
AU - Schlaak, Max
AU - Booken, Nina
AU - Wobser, Marion
AU - Mitteldorf, Christina
AU - Aviv, Barzilai
AU - Mareco, Virgínia
AU - Gallardo, Fernando
AU - Dummer, Reinhard
AU - Gross, Markus
AU - Ehret, Felix
AU - Lancia, Andrea
AU - Tomasik, Bartłomiej
AU - Hawley, Lorna
AU - Rermouchamps, Vincent
AU - Ibrahim, Mona Abdel Halim
AU - Gawish, Ahmed
AU - Abouegylah, Mohamed
AU - Stuschke, Martin
AU - Baten, Adinda
AU - Eich, Hans Theodor
AU - Specht, Lena
AU - Levis, Mario
AU - Morris, Stephen
AU - Campbell, Belinda
AU - Nicolay, Jan P.
AU - Cowan, Richard
AU - Correia, Dora
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2025/3/15
Y1 - 2025/3/15
N2 - Purpose: We aim to determine the current treatment patterns and recommendations among physicians for cutaneous lymphomas and to identify the types of skin lymphomas for which existing radiation regimens need improvement. Methods and Materials: A questionnaire from the European Organisation for Research and Treatment of Cancer was distributed to all members of the Cutaneous Lymphoma Tumour Group and Radiation Oncology Scientific Council. This online survey included 13 questions regarding treatment practices for patients with cutaneous lymphoma. The survey was conducted from August 21 to December 18, 2023. Frequency distributions and subgroup comparisons were calculated and analyzed. Results: We collected 51 completed questionnaires from investigators from 19 countries specializing in cutaneous lymphoma treatment. Radiation doses varied significantly (range, 4-60 Gy). Based on the histologic entity, up to one-third of the investigators delivered hypofractionated regimens (range, 14%-35%). Reduced-dose radiation therapy (RT) was considered by 27% to 63% of investigators. Meanwhile, 18 (35%) investigators considered adapting the radiation dose to the response to immunochemotherapy when treating primary cutaneous diffuse large B cell lymphoma-leg type. Regarding total skin electron beam therapy, 91% of centers delivered reduced-dose regimens, and 18% of investigators applied ultrahypofractionated protocols. Conclusions: RT in patients with cutaneous lymphoma is highly heterogeneous among the European Organisation for Research and Treatment of Cancer centers. The development of evidence-based recommendations for RT dose, fractionation, and technique for cutaneous lymphomas is required for optimization and standardization of treatment.
AB - Purpose: We aim to determine the current treatment patterns and recommendations among physicians for cutaneous lymphomas and to identify the types of skin lymphomas for which existing radiation regimens need improvement. Methods and Materials: A questionnaire from the European Organisation for Research and Treatment of Cancer was distributed to all members of the Cutaneous Lymphoma Tumour Group and Radiation Oncology Scientific Council. This online survey included 13 questions regarding treatment practices for patients with cutaneous lymphoma. The survey was conducted from August 21 to December 18, 2023. Frequency distributions and subgroup comparisons were calculated and analyzed. Results: We collected 51 completed questionnaires from investigators from 19 countries specializing in cutaneous lymphoma treatment. Radiation doses varied significantly (range, 4-60 Gy). Based on the histologic entity, up to one-third of the investigators delivered hypofractionated regimens (range, 14%-35%). Reduced-dose radiation therapy (RT) was considered by 27% to 63% of investigators. Meanwhile, 18 (35%) investigators considered adapting the radiation dose to the response to immunochemotherapy when treating primary cutaneous diffuse large B cell lymphoma-leg type. Regarding total skin electron beam therapy, 91% of centers delivered reduced-dose regimens, and 18% of investigators applied ultrahypofractionated protocols. Conclusions: RT in patients with cutaneous lymphoma is highly heterogeneous among the European Organisation for Research and Treatment of Cancer centers. The development of evidence-based recommendations for RT dose, fractionation, and technique for cutaneous lymphomas is required for optimization and standardization of treatment.
UR - http://www.scopus.com/inward/record.url?scp=85211350809&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2024.11.011
DO - 10.1016/j.ijrobp.2024.11.011
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39549760
AN - SCOPUS:85211350809
SN - 0360-3016
VL - 121
SP - 1006
EP - 1010
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -
